Genetic counselling and testing for inherited dementia: single-centre evaluation of the consensus Italian DIAfN protocol.
Alzheimer’s disease
Dementia
Frontotemporal dementia
Genetic counselling
Genetic testing
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
17 11 2020
17 11 2020
Historique:
received:
13
08
2020
accepted:
03
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
25
6
2021
Statut:
epublish
Résumé
A consensus protocol for genetic counselling and testing of familial dementia, the Italian Dominantly Inherited Alzheimer's and Frontotemporal Network (IT-DIAfN) protocol, has been developed in Italy by a network of expert dementia centres. The aim of this study is to evaluate feasibility and acceptability of the genetic counselling and testing process, as undertaken according to the IT-DIAfN protocol in one of the IT-DIAfN dementia research centres. The protocol was tested by a multidisciplinary team at the IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, on affected individuals with suspected inherited forms of Alzheimer's disease (AD) or frontotemporal dementia (FTD), and to healthy at-risk relatives. The genetic counselling and testing process consisted of (i) pre-test consultation and psychological assessment (ii) genetic testing, (iii) genetic test result disclosure and (iv) follow-up consultation and psychological assessment. Twenty affected individuals from 17 families fulfilled the family history criteria of the IT-DIAfN protocol for suspected inherited dementia (17 for AD, 2 for FTD, 1 for inclusion body myopathy with Paget disease of bone and frontotemporal dementia) and were included in the protocol. Nineteen out of 20 affected individuals received the genetic test result (one left after the pre-test consultation being not ready to cope with an unfavourable outcome). A pathogenic mutation was found in 6 affected individuals (1 in PSEN1, 2 in PSEN2, 1 in GRN, 1 in MAPT, 1 in VCP). Eleven healthy at-risk relatives asked to undergo predictive testing and were included in the protocol. Three completed the protocol, including follow-up; one did not ask for the genetic test result after genetic testing; and eight withdrew before the genetic testing, mainly due to an increased awareness about the possible consequences of an unfavourable test result. To date, no catastrophic reactions were reported at the follow-up. Our case series shows that a structured genetic counselling and testing protocol for inherited dementia can be implemented in both affected individuals and at-risk relatives in a research setting. The procedure was shown to be safe in terms of occurrence of catastrophic events. A formal validation in larger cohorts is needed.
Sections du résumé
BACKGROUND
A consensus protocol for genetic counselling and testing of familial dementia, the Italian Dominantly Inherited Alzheimer's and Frontotemporal Network (IT-DIAfN) protocol, has been developed in Italy by a network of expert dementia centres. The aim of this study is to evaluate feasibility and acceptability of the genetic counselling and testing process, as undertaken according to the IT-DIAfN protocol in one of the IT-DIAfN dementia research centres.
METHODS
The protocol was tested by a multidisciplinary team at the IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, on affected individuals with suspected inherited forms of Alzheimer's disease (AD) or frontotemporal dementia (FTD), and to healthy at-risk relatives. The genetic counselling and testing process consisted of (i) pre-test consultation and psychological assessment (ii) genetic testing, (iii) genetic test result disclosure and (iv) follow-up consultation and psychological assessment.
RESULTS
Twenty affected individuals from 17 families fulfilled the family history criteria of the IT-DIAfN protocol for suspected inherited dementia (17 for AD, 2 for FTD, 1 for inclusion body myopathy with Paget disease of bone and frontotemporal dementia) and were included in the protocol. Nineteen out of 20 affected individuals received the genetic test result (one left after the pre-test consultation being not ready to cope with an unfavourable outcome). A pathogenic mutation was found in 6 affected individuals (1 in PSEN1, 2 in PSEN2, 1 in GRN, 1 in MAPT, 1 in VCP). Eleven healthy at-risk relatives asked to undergo predictive testing and were included in the protocol. Three completed the protocol, including follow-up; one did not ask for the genetic test result after genetic testing; and eight withdrew before the genetic testing, mainly due to an increased awareness about the possible consequences of an unfavourable test result. To date, no catastrophic reactions were reported at the follow-up.
CONCLUSIONS
Our case series shows that a structured genetic counselling and testing protocol for inherited dementia can be implemented in both affected individuals and at-risk relatives in a research setting. The procedure was shown to be safe in terms of occurrence of catastrophic events. A formal validation in larger cohorts is needed.
Identifiants
pubmed: 33203472
doi: 10.1186/s13195-020-00720-4
pii: 10.1186/s13195-020-00720-4
pmc: PMC7670800
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
152Références
Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):301
pubmed: 19730171
Int J Behav Med. 1997;4(1):92-100
pubmed: 16250744
J Alzheimers Dis. 2018;61(2):753-760
pubmed: 29226869
J Neurol. 2019 Aug;266(8):2075-2086
pubmed: 31119452
Eur J Hum Genet. 2000 Oct;8(10):731-8
pubmed: 11039571
Psychiatr Clin North Am. 2015 Jun;38(2):295-308
pubmed: 25998117
J Alzheimers Dis. 2016;51(1):277-91
pubmed: 26901402
Genet Test. 2005 Summer;9(2):152-7
pubmed: 15943556
J Neurol Neurosurg Psychiatry. 2000 Nov;69(5):574-8
pubmed: 11032605
Ital J Neurol Sci. 1998 Apr;19(2):68-74
pubmed: 10935839
Neurology. 2016 Jun 14;86(24):2295-302
pubmed: 27194384
Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Alzheimer Dis Assoc Disord. 2003 Apr-Jun;17(2):86-93
pubmed: 12794385
J Med Genet. 1997 Jan;34(1):63-72
pubmed: 9032652
PLoS One. 2019 Aug 5;14(8):e0219755
pubmed: 31381569
Folia Neuropathol. 2014;52(4):457-66
pubmed: 25574752
J Alzheimers Dis. 2012;31(1):7-11
pubmed: 22531416
BMC Public Health. 2006 Jun 16;6:155
pubmed: 16780576
Eur J Hum Genet. 2018 May;26(5):605-615
pubmed: 29422659
Eur J Hum Genet. 2016 Oct;24(10):1396-402
pubmed: 27165004
Alzheimers Res Ther. 2011 Jan 06;3(1):1
pubmed: 21211070
Neuropathol Appl Neurobiol. 2000 Aug;26(4):368-78
pubmed: 10931371
Arch Neurol. 2001 Nov;58(11):1828-31
pubmed: 11708991
Braz J Med Biol Res. 2011 Apr;44(4):374-80
pubmed: 21412659
J Alzheimers Dis. 2019;67(1):243-256
pubmed: 30530974
Neurogenetics. 2008 Jul;9(3):197-205
pubmed: 18392865
Neuropathol Appl Neurobiol. 2005 Aug;31(4):362-73
pubmed: 16008820
Clin Neuropathol. 2007 Sep-Oct;26(5):232-40
pubmed: 17907600
Curr Protoc Mol Biol. 2018 Apr;122(1):e59
pubmed: 29851291
Int Rev Psychiatry. 2013 Apr;25(2):130-7
pubmed: 23611343
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
J Alzheimers Dis. 2012;30(4):847-56
pubmed: 22475797
J Genet Couns. 2009 Aug;18(4):350-6
pubmed: 19360462
Neurol Sci. 2012 Apr;33(2):375-8
pubmed: 21822699
Intern Med. 2019 Aug 15;58(16):2397-2400
pubmed: 30996196
J Med Genet. 1996 Sep;33(9):737-43
pubmed: 8880572
Genet Med. 2006 Nov;8(11):673-80
pubmed: 17108758
Clin Interv Aging. 2018 Sep 27;13:1847-1857
pubmed: 30310270
Neurobiol Aging. 2008 Mar;29(3):427-35
pubmed: 17157414
Alzheimers Dement. 2017 Jan;13(1):8-19
pubmed: 27583651
Cold Spring Harb Perspect Med. 2020 Jul 1;10(7):
pubmed: 31548223
Brain. 2008 Mar;131(Pt 3):732-46
pubmed: 18245784
Int J Methods Psychiatr Res. 2005;14(1):29-42
pubmed: 16097398
Am J Hum Genet. 1995 Jan;56(1):332-5
pubmed: 7825596
Neurologia. 2011 Apr;26(3):143-9
pubmed: 21163230
J Genet Couns. 2006 Apr;15(2):77-83
pubmed: 16761103
Mol Genet Metab. 2011 Apr;102(4):494-504
pubmed: 21220204
Brain. 2007 Feb;130(Pt 2):381-93
pubmed: 16984901
Neurology. 2006 Aug 22;67(4):644-51
pubmed: 16790606
Neurology. 2009 Nov 3;73(18):1451-6
pubmed: 19884572
Health Educ Monogr. 1978 Spring;6(2):160-70
pubmed: 689890
Neurology. 2000 May 23;54(10):2006-8
pubmed: 10822446
J Huntingtons Dis. 2019;8(4):435-441
pubmed: 31381523
Brain Pathol. 1998 Apr;8(2):387-402
pubmed: 9546295
Neurobiol Dis. 2009 Mar;33(3):379-85
pubmed: 19101631
Genet Med. 2012 Sep;14(9):765-76
pubmed: 22498847
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Arch Neurol. 2010 Feb;67(2):161-70
pubmed: 20142524
Am J Hum Genet. 1994 Oct;55(4):618-25
pubmed: 7942839
Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):249-51
pubmed: 25010293
J Neurol Sci. 2009 Dec 15;287(1-2):291-3
pubmed: 19683260
Genet Med. 2011 Jun;13(6):597-605
pubmed: 21577118